CN102065842A - 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物 - Google Patents

优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物 Download PDF

Info

Publication number
CN102065842A
CN102065842A CN2009801224878A CN200980122487A CN102065842A CN 102065842 A CN102065842 A CN 102065842A CN 2009801224878 A CN2009801224878 A CN 2009801224878A CN 200980122487 A CN200980122487 A CN 200980122487A CN 102065842 A CN102065842 A CN 102065842A
Authority
CN
China
Prior art keywords
posaconazole
composition
compositions
hpmc
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801224878A
Other languages
English (en)
Chinese (zh)
Inventor
L.Y.方
D.哈里斯
G.克里什娜
A.E.小莫顿
R.C.普雷斯蒂皮诺
M.施泰因曼
J.万
H.A.瓦斯金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41199703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102065842(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Priority to CN201510421108.2A priority Critical patent/CN104983701A/zh
Publication of CN102065842A publication Critical patent/CN102065842A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801224878A 2008-04-15 2009-04-15 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物 Pending CN102065842A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510421108.2A CN104983701A (zh) 2008-04-15 2009-04-15 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4517708P 2008-04-15 2008-04-15
US61/045177 2008-04-15
US16648709P 2009-04-03 2009-04-03
US61/166487 2009-04-03
PCT/US2009/040652 WO2009129300A2 (en) 2008-04-15 2009-04-15 High density compositions containing posaconazole and formulations comprising the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510421108.2A Division CN104983701A (zh) 2008-04-15 2009-04-15 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物

Publications (1)

Publication Number Publication Date
CN102065842A true CN102065842A (zh) 2011-05-18

Family

ID=41199703

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510421108.2A Pending CN104983701A (zh) 2008-04-15 2009-04-15 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物
CN2009801224878A Pending CN102065842A (zh) 2008-04-15 2009-04-15 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510421108.2A Pending CN104983701A (zh) 2008-04-15 2009-04-15 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物

Country Status (19)

Country Link
US (2) US20110123627A1 (enExample)
EP (1) EP2285351A2 (enExample)
JP (3) JP2011516612A (enExample)
KR (1) KR20110004852A (enExample)
CN (2) CN104983701A (enExample)
AR (1) AR072858A1 (enExample)
AU (1) AU2009236289B2 (enExample)
BR (1) BRPI0910627A2 (enExample)
CA (1) CA2720849A1 (enExample)
CL (1) CL2009000902A1 (enExample)
CO (1) CO6311066A2 (enExample)
MX (1) MX2010011295A (enExample)
NZ (1) NZ588460A (enExample)
PE (1) PE20091778A1 (enExample)
PH (1) PH12015500492A1 (enExample)
SG (1) SG10201403986UA (enExample)
TW (1) TWI388324B (enExample)
WO (1) WO2009129300A2 (enExample)
ZA (1) ZA201007370B (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104208713A (zh) * 2013-06-03 2014-12-17 信越化学工业株式会社 用于热熔挤出的组合物以及用其制备热熔挤出产品的方法
CN104371030A (zh) * 2013-08-12 2015-02-25 信越化学工业株式会社 用作热熔挤出载体的醋酸琥珀羟丙甲纤维素、热熔挤出组合物及生产热熔挤出物的方法
CN104510707A (zh) * 2013-09-26 2015-04-15 博瑞生物医药技术(苏州)有限公司 一种泊沙康唑固体分散体及其制备方法
CN104546667A (zh) * 2013-10-22 2015-04-29 博瑞生物医药技术(苏州)有限公司 含泊沙康唑的固体分散体及其制备方法
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
CN106265526A (zh) * 2016-09-22 2017-01-04 山东大学 一种抗真菌药物泊沙康唑的固体分散体及制备方法与应用
CN112697937A (zh) * 2020-12-18 2021-04-23 卓和药业集团有限公司 泊沙康唑肠溶片溶出度的分析方法
CN114184721A (zh) * 2021-12-14 2022-03-15 江苏恒盛药业有限公司 泊沙康唑残留溶剂的检测方法
CN115721601A (zh) * 2022-11-23 2023-03-03 无锡福祈制药有限公司 一种泊沙康唑纳米晶口服固体药物组合物及其制备方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011516613A (ja) * 2008-04-15 2011-05-26 シェーリング コーポレイション 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
JP5749247B2 (ja) 2010-02-22 2015-07-15 第一三共株式会社 経口用徐放性固形製剤
RU2019123406A (ru) 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
CN104971045A (zh) * 2014-04-11 2015-10-14 上海宣泰医药科技有限公司 泊沙康唑药物组合物及其制备方法和药物制剂
WO2017025292A1 (en) 2015-08-08 2017-02-16 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant formulation containing posaconazole
EP4424308A3 (en) 2016-02-26 2024-12-04 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor
WO2017032908A1 (en) 2016-07-08 2017-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous posaconazole
TR201620462A2 (tr) 2016-12-31 2018-07-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
US20180282527A1 (en) * 2017-03-30 2018-10-04 Shin-Etsu Chemical Co., Ltd. Injection molding composition containing hypromellose acetate succinate and method for producing same
US10702520B1 (en) 2019-01-29 2020-07-07 Slayback Pharma Llc Pharmaceutical compositions of posaconazole
US20230149452A1 (en) * 2020-04-06 2023-05-18 Yogesh BENDALE Structurally defined, better tolerated, orally adminstered, processed arsenolite, a process for its preparation, a pharmaceutical composition and uses thereof
US20240293399A1 (en) 2020-08-13 2024-09-05 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant high-strength formulation containing posaconazole
EP4091604B1 (en) 2021-11-25 2024-04-03 Alfred E. Tiefenbacher (GmbH & Co. KG) Granules containing posaconazole
WO2023012378A1 (en) 2021-11-25 2023-02-09 Alfred E. Tiefenbacher (Gmbh Und Co. Kg) Granules containing posaconazole

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
US5661151A (en) * 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
US5703079A (en) * 1993-12-21 1997-12-30 Schering Corporation Tetrahydrofuran antifungals
NZ270418A (en) * 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
CN1165291C (zh) * 1996-05-20 2004-09-08 詹森药业有限公司 具有改进的生物利用度的抗真菌组合物
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
CA2396380C (en) * 1999-12-23 2015-04-21 David Hayes Improved pharmaceutical compositions for poorly soluble drugs
UY26615A1 (es) * 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
EP1372394A1 (en) * 2001-04-03 2004-01-02 Schering Corporation Antifungal composition with enhanced bioavailability
WO2003077827A1 (en) * 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Process for producing drug solid dispersion
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
US20060062848A1 (en) * 2004-09-17 2006-03-23 Nektar Therapeutics Uk Limited Formulation comprising itraconazole
US20060275230A1 (en) * 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
JP2009514884A (ja) * 2005-11-04 2009-04-09 イーストマン ケミカル カンパニー 難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル
CN101495096A (zh) * 2006-05-30 2009-07-29 伊兰制药国际有限公司 纳米微粒泊沙康唑制剂
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
JP2011516613A (ja) * 2008-04-15 2011-05-26 シェーリング コーポレイション 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104208713A (zh) * 2013-06-03 2014-12-17 信越化学工业株式会社 用于热熔挤出的组合物以及用其制备热熔挤出产品的方法
CN105283203A (zh) * 2013-06-03 2016-01-27 信越化学工业株式会社 用于热熔挤出的组合物以及通过使用该组合物制备热熔挤出物的方法
CN105283203B (zh) * 2013-06-03 2018-12-28 信越化学工业株式会社 用于热熔挤出的组合物以及通过使用该组合物制备热熔挤出物的方法
US10646573B2 (en) 2013-06-03 2020-05-12 Shin-Etsu Chemical Co., Ltd. Composition for hot melt extrusion and method for producing hot melt extrudate by using same
CN104371030A (zh) * 2013-08-12 2015-02-25 信越化学工业株式会社 用作热熔挤出载体的醋酸琥珀羟丙甲纤维素、热熔挤出组合物及生产热熔挤出物的方法
CN104510707A (zh) * 2013-09-26 2015-04-15 博瑞生物医药技术(苏州)有限公司 一种泊沙康唑固体分散体及其制备方法
CN104546667A (zh) * 2013-10-22 2015-04-29 博瑞生物医药技术(苏州)有限公司 含泊沙康唑的固体分散体及其制备方法
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
CN106265526A (zh) * 2016-09-22 2017-01-04 山东大学 一种抗真菌药物泊沙康唑的固体分散体及制备方法与应用
CN112697937A (zh) * 2020-12-18 2021-04-23 卓和药业集团有限公司 泊沙康唑肠溶片溶出度的分析方法
CN114184721A (zh) * 2021-12-14 2022-03-15 江苏恒盛药业有限公司 泊沙康唑残留溶剂的检测方法
CN115721601A (zh) * 2022-11-23 2023-03-03 无锡福祈制药有限公司 一种泊沙康唑纳米晶口服固体药物组合物及其制备方法

Also Published As

Publication number Publication date
MX2010011295A (es) 2010-11-12
AU2009236289A1 (en) 2009-10-22
US20110123627A1 (en) 2011-05-26
PH12015500492A1 (en) 2017-04-10
KR20110004852A (ko) 2011-01-14
EP2285351A2 (en) 2011-02-23
WO2009129300A3 (en) 2010-02-11
JP2016074698A (ja) 2016-05-12
PE20091778A1 (es) 2009-11-13
CN104983701A (zh) 2015-10-21
NZ588460A (en) 2012-07-27
AU2009236289B2 (en) 2014-08-21
CL2009000902A1 (es) 2010-07-23
TW200946121A (en) 2009-11-16
AR072858A1 (es) 2010-09-29
JP2014139230A (ja) 2014-07-31
TWI388324B (zh) 2013-03-11
JP2011516612A (ja) 2011-05-26
BRPI0910627A2 (pt) 2015-09-22
CA2720849A1 (en) 2009-10-22
ZA201007370B (en) 2011-06-29
SG10201403986UA (en) 2014-10-30
US20150150990A1 (en) 2015-06-04
WO2009129300A2 (en) 2009-10-22
CO6311066A2 (es) 2011-08-22

Similar Documents

Publication Publication Date Title
CN102065842A (zh) 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物
US5340589A (en) Low solubility drug-coated bead compositions
US20230248655A1 (en) Tablet formulation for cgrp active compounds
US8354122B2 (en) Solid dispersion preparation
EP2953615B1 (en) Solid dispersion comprising amorphous cilostazol
US20210128536A1 (en) Weakly basic drug and ionic polymer pharmaceutical formulations and methods of formation and administration thereof
CN113081970A (zh) 一种环孢素固体分散体及其片剂制备方法
EP3572069A1 (en) Increasing solubility and bioavailability of enzalutamide
AU2014265059A1 (en) Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
WO2024024938A1 (ja) デラマニド含有固体分散体
HK40090396A (zh) 包含环状膦酸酯化合物的药物组合物及其制备方法与用途
HK1218618B (en) Solid dispersion comprising amorphous cilostazol

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: new jersey

Applicant after: Schering Corporation

Address before: new jersey

Applicant before: SCHERING CORP (US)

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: SCHERING CORP (US) TO: MSD CORP.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110518